Publication: Vaccines
By: Stine Hansen, Kim Thomsen, Andreas Holm Mattsson, Pär Comstedt, Claus Moser & Oana Ciofu

Our CEO Christian Kanstrup attended the Sidoti & Company, LLC Micro Cap Conference to meet investors and present Evaxion, our AI-Immunology platform, strategy and value catalysts.

Are you eager to deep-dive into Evaxion's business? Download our company presentation.

T-cell immunogenicity and biomarker profiling in advanced melanoma patients receiving the personalized vaccine EVX-01 in combination with pembrolizumab

In this interview, our CEO, Christian Kanstrup, provides a status on Evaxion's Innovative AI-Immnuology™ platform and broad pipeline within cancer and infectious disease vaccines. 

Publication: npj Vaccines
By: Christian Garde, Michail A. Pavlidis, Pablo Garces, Emma J. Lange, Sri H. Ramarathinam, Mateo Sokač, Kirti Pandey, Pouya Faridi, Johanne Ahrenfeldt, Shanzou Chung, Stine Friis, Daniela Kleine-Kohlbrecher, Nicolai J. Birkbak, Jens V. Kringelum, Birgitte Rønø, Anthony W. Purcell & Thomas Trolle

In this interview, our CEO, Christian Kanstrup, walks you through Evaxion’s vision— Decoding the human immune system to develop novel vaccines for cancer and infectious diseases with our AI-Immunology™ platform.

Our Chief Executive Officer, Christian Kanstrup, and Chief Scientific Officer, Birgitte Rønø, had the pleasure yesterday of presenting our AI-Immunology platform, pipeline and strategy in conversation with Ramakanth Swayampakula, Senior Healthcare Analyst at H.C. Wainwright & Co., LLC.

In our latest interview on the BigBiz Show, we dive into: 

• Our vision to utilize AI to address serious unmet medical need and allow people to live healthier lives
• The latest advancements in EVX-01, currently in phase 2 of clinical development
• How our strategic partnership with MSD supports groundbreaking innovation in infectious disease therapies 
• The transformative potential of personalized cancer vaccines, which could target multiple solid tumors 

AI-designed cancer vaccines: antigens from the dark genome are promising cancer vaccine targets